• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

AmerisourceBergen Launches Pharmacy Telehealth Pilot with SteadyMD

by Fred Pennic 05/04/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
AmerisourceBergen Launches Pharmacy Telehealth Pilot with SteadyMD

What You Should Know:

  • AmerisourceBergen (AB), a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider for the co-creation of a telehealth solution focused on Test to Treat opportunities. The solution is being offered as a pilot to independent community pharmacies across the US.
  • In addition to the commercial partnership, AmerisourceBergen has also made a minority investment in SteadyMD through its venture fund AB Health Ventures.

Test to Treat Pilot

AmerisourceBergen’s telehealth solution is being developed to expand the number of Test to Treat services that independent pharmacies can offer to patients. The Test to Treat initiative was launched in 2022 to help provide quick and equitable access to COVID-19 testing and treatment in the early days of infection. The model is intended to provide a seamless patient experience and designed to reach high-risk, underserved populations.

With its telehealth solution, AmerisourceBergen is evaluating the long-term viability of the Test to Treat model for use cases, beyond COVID-19, to improve access to treatment. The pilot program has been launched across a group of 130 independent retail pharmacies, including members of the Good Neighbor Pharmacy network. Over a span of 12 weeks, pilot participants will utilize the SteadyMD platform to provide patients with a quick and accessible Test to Treat option within their pharmacy, at an affordable price. Patients can test for an illness or condition and then, if deemed necessary by a SteadyMD physician, consult with them on demand through the telehealth platform and receive a prescription for treatment.

Pharmacies participating in the telehealth pilot program can use the solution to help patients obtain COVID-19 oral antiviral therapies, as appropriate. AmerisourceBergen and SteadyMD will continuously evaluate opportunities to expand use cases during and after the program.

“The Test to Treat initiative is an important acknowledgement of the role of pharmacists and pharmacies as accessible healthcare providers and destinations,” said Jenni Zilka, Senior Vice President, Good Neighbor Pharmacy Field Programs & Services at AmerisourceBergen. “In order for pharmacies to continue making a sustainable impact on the communities they serve, we need to continue providing them the tools, resources, and authority to provide necessary clinical services, where appropriate. AmerisourceBergen’s exploration of a telehealth solution with SteadyMD to enhance the scope of the Test to Treat model is just one way we’re continuing to support the important role of the pharmacist in the healthcare ecosystem.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: global healthcare, Health Ventures, model, Patient Experience, Pharmacy, risk

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |